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Chronic renal allograft rejection is characterized by
alterations in the extracellular matrix compartment and in
the proliferation of various cell types. These features are
controlled, in part by the metzincin superfamily of
metallo-endopeptidases, including matrix metalloproteinases
(MMPs), a disintegrin and metalloproteinase (ADAM) and
meprin. Therefore, we investigated the regulation of
metzincins in the established Fisher to Lewis rat kidney
transplant model. Studies were performed using frozen
homogenates and paraffin sections of rat kidneys at day 0
(healthy controls) and during periods of chronic rejection at
day þ 60 and day þ 100 following transplantation. The
messenger RNA (mRNA) expression was examined by
Affymetrix Rat Expression Array 230A GeneChip and by
real-time Taqman polymerase chain reaction analyses.
Protein expression was studied by zymography, Western blot
analyses, and immunohistology. mRNA levels of MMPs
(MMP-2/-11/-12/-14), of their inhibitors (tissue inhibitors of
metalloproteinase (TIMP)-1/-2), ADAM-17 and transforming
growth factor (TGF)-b1 significantly increased during
chronic renal allograft rejection. MMP-2 activity and
immunohistological staining were augmented accordingly.
The most important mRNA elevation was observed in the
case of MMP-12. As expected, Western blot analyses also
demonstrated increased production of MMP-12, MMP-14,
and TIMP-2 (in the latter two cases as individual proteins and
as complexes). In contrast, mRNA levels of MMP-9/-24 and
meprin a/b had decreased. Accordingly, MMP-9 protein levels
and meprin a/b synthesis and activity were downregulated
significantly. Members of metzincin families (MMP, ADAM,
and meprin) and of TIMPs are differentially regulated in
chronic renal allograft rejection. Thus, an altered pattern of
metzincins may represent novel diagnostic markers and
possibly may provide novel targets for future therapeutic
interventions.
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The two main causes responsible for late renal allograft
failure are chronic rejection, a major contributor to chronic
allograft nephropathy, and patient death with a functioning
transplant.1 Therapy and precise diagnosis of chronic
rejection remain difficult. Therefore, the definition of new
diagnostic markers and of novel therapeutic targets continue
to be of great clinical relevance.
Alterations in the extracellular matrix (ECM) compartment
and in the proliferation rates of various cell types are key
features in chronic allograft nephropathy, including chronic
rejection processes.2 The metabolism of ECM proteins in the
kidney is influenced substantially by the metzincin superfamily
of metalloendopeptidases, notably by matrix metalloprotein-
ases (MMPs)3,4 and to some extent also by meprin5–7 and by a
disintegrin and metalloproteinases (ADAMs).8,9
MMPs are traditionally classified into four categories,
namely interstitial collagenases (MMP-1/-8/-13), gelatinases
(MMP-2/-9), stromelysins (MMP-3/-7/-10/-11/-12) and
membrane-type -MMP (MMP-14/-15/-16/-17).10,11
The main function of MMPs is the degradation of ECM
proteins and to a lesser extent the regulation of cell
proliferation.4,12–14 Reversible MMP inhibition occurs by
their natural inhibitors, tissue inhibitors of metalloprotein-
ases (TIMPs).15 MMPs represent important mediators in
inflammatory diseases and also in tumor invasion, kidney
morphogenesis and bone turnover.3,11,16–20
MMPs may act as proinflammatory mediators in allograft
rejection in several ways: direct tissue injury,10,11 augmenta-
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tion of cell proliferation and/or migration4,14,21 and facilita-
tion of tissue invasion by extrinsic cells (e.g. leukocytes).20
Meprin represents either a cell-surface bound or a secreted
zinc endopeptidase of the astacin family of the metzincins.5–7,22
This protease is composed of a and b subunits of
approximately 85–110 kDa, respectively, that form homo- and
hetero-oligomeric complexes.7,23 Rat meprin A exists either as
homo-oligomers of a subunits or as heterodimers or tetramers
of a and b subunits.7,23 On the contrary, rat meprin B consists
essentially of homo-oligomeric b subunits.7,23 Only the homo-
oligomers of meprin A are secreted proteins.7 Meprin B and
hetero-oligomers of meprin A remain membrane bound.7
Meprin is highly regulated and is strongly expressed at the
brush border membranes of renal proximal tubular cells and
intestinal epithelial cells.5,24 Meprin cleaves a wide range of
peptides and proteins, including collagen type IV, laminin,
fibronectin, and nidogen.22–25
With respect to the kidney, meprin has been investigated
in experimental ischemia and reperfusion injury.5,26 Mice
expressing lower meprin A levels in the kidney showed a
decreased degree of renal damage as a result of ischemia and
reperfusion.27 Meprin was found to be cytotoxic to renal
tubular epithelial cells and its inhibition by actinonin
ameliorated ischemia–reperfusion injury in rats.5
The ADAMs represent a family of membrane proteins
containing a disintegrin and metalloprotease domain.8,9 The
main substrates of ADAM are integral membrane or ECM
proteins. Altered ADAM expression has been found in several
disorders including asthma, arthritis, Alzheimer’s disease,
atherosclerosis, and malignancy.8,9 We focused on ADAM-17
(tumour necrosis factor-a converting enzyme) due to its
prominent role in inflammation.28
In our present studies, we analyzed the regulation of a
wide spectrum of metzincins in the Fisher (F344) to Lewis
(LEW) kidney transplant model.29,30 Two time points of
chronic rejection were chosen, days þ 60 and þ 100 after
transplantation.29,30
RESULTS
F344 to LEW renal transplant model
For our studies, we used the well-established F344 to LEW
kidney transplant model. This experimental model has been
extensively described in the past.29,30 Importantly, LEW
recipients develop acute rejection at approximately day þ 25
for several days, followed by chronic rejection beyond day
þ 50 after transplantation. Chronic rejection is characterized
by severe histological alterations as well as by increases in
microalbuminuria and serum creatinine levels, as shown in
Figure 1 and Table 1, and as previously reported.29,30
Affymetrix GeneChip analysis
Results of Affymetrix Rat Expression Array 230A GeneChip
analysis are summarized in Table 2. Significant upregulation
was observed for MMP-11/-12/-14, ADAM-17, TIMP-1/-2
and transforming growth factor (TGF)-b1 during chronic
rejection at day þ 60 and day þ 100 (with the exception
of ADAM-17 and MMP-11). Levels of these two proteases
failed to reach statistical significance at a later time point
(day þ 100).
In contrast, MMP-9 and meprin a messenger RNA
(mRNA) substantially decreased as a result of the chronic
rejection process at both time points and MMP-24 was
reduced significantly at day þ 60.
MMP-2/-3/-7/-8/-10/-16/-23, ADAM-10 and TIMP-3 gene
expression remained unchanged during the rejection process.
To complete our studies, we investigated selected metzin-
cin substrates, as shown in Table 2. As expected from the
histological alterations commonly seen in chronic allograft
rejection and from previous descriptions of our model,29,30
Day 0 Day + 60 Day +100 
Figure 1 | Renal histology. Left panel: healthy control kidney (day 0).
Middle panel: chronic rejection of an F344 renal allograft at day þ 60
demonstrating glomerular and tubulo-interstitial alterations, as
scored in Table 1 (Periodic acid-Schiff staining). Right panel: chronic
rejection at day þ 100 depicting similar histological alterations, as
compared to day þ 60.
Table 1 | Histological and functional characteristics of chronic allograft rejection
Interstitial infiltrate,
tubular atrophy,
fibrin in glomeruli,
mesangiolysis,
glomerulitis
Interstitial
fibrosis
Arterial
fibrointimal
hyperplasia
Microalbuminurea7s.d.
(mg/24 h)
Creatinine
(serum)7s.d.
(lmol/l)
Day 0a 0b 0b 0b 0.570.13 48.6773.06
Days +60 to +100c 2b 3b 1b 10.5179.74 79.43710.47
an=8.
bBanff classification.29,31
cn=12 (day +60) and n=6 (day +100).
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there was a significant upregulation of mRNA collagens I a1,
I a2, III a1and IV a1 at day þ 60.
Subsequently, significant results regarding metzincins were
further investigated and confirmed by real-time polymerase
chain reaction (PCR) analysis. Despite the negative GeneChip
results, we further analyzed MMP-2/-7/-8, TIMP-3 and
meprin. MMP-2 is particularly relevant, as it represents
one of the most extensively investigated MMP in infla-
mmatory disorders. Owing to the clear trend towards a
decrease, meprin b also warranted additional investigations.
Because of their biological relevance in inflammation,
MMP-7/-8 and TIMP-3 were also included in the real-time
PCR analyses.32
Because glyceraldehyde-3-phosphate dehydrogenase
(GAPDH), represented by three different probe sets on the
microarray, was not regulated and remained constant
between the three different groups (data not shown), we
were able to use it as a housekeeping gene for normalizing
data in the subsequent real-time PCR analyses.
Real-time reverse transcriptase-polymerase chain reaction
analyses of MMP, TIMP, ADAM-17, and TGF-b1
Affymetrix GeneChip results were validated by real-time
quantitative reverse transcriptase-polymerase chain reaction
at days 0 (n¼ 8), þ 60 (n¼ 12) and þ 100 (n¼ 6). These
results are summarized in Figure 2a. The respective native
contralateral kidneys from day 0 served as healthy controls
and their values are depicted as 1.
During the rejection process, mRNA levels of MMP-2/
-11/-14 and particularly MMP-12 increased (approx. 5.2/2.6/
2.4/67.7-fold, respectively), as well as TIMP-1/-2 (approx.
10.5/2.5-fold) and ADAM-17 (1.7-fold at day þ 60).
However, MMP-9 decreased (approx. 7.5-fold) and TIMP-3
remained unchanged. As expected, TGF-b1 (positive control)
was also augmented (6.8-fold and 4.3-fold at days þ 60 and
þ 100, respectively). For all these comparisons between day 0
and days þ 60 or þ 100, Po0.05.
As depicted in Figure 2b, MMP-7 remained below the
detection limit in all control samples of day 0 (n¼ 8; CT
values X40). During chronic rejection, MMP-7 was detect-
able in 10/12 samples at day þ 60 and in all samples at day
þ 100 (n¼ 6). Therefore, MMP-7 was significantly upregu-
lated in chronic allograft rejection at both time points
(Po0.05).
With regard to MMP-8, half of the control samples from
day 0 were below the detection limit (n¼ 8; CT values X40).
At day þ 60, the results for 10/12 samples were hetero-
geneous and two samples were below the detection limit. All
Table 2 | Affymetrix GeneChip analysis of 25 genes (12 MMP, three TIMP, two ADAM, two meprins, TGF-b1, four collagens, and
a proteoglycan core protein) expressed in allografts with chronic rejection (samples at day +60 and day +100) and in healthy
kidney controls (samples at day 0)
Gene
RefSeq/GenBank
accession no.
Affymetrix
probe set Day 0 Day +60 Day +100
MMP-2 NM_031054 1369825_at 23.877.6 18.676.3 15.574.2
MMP-3 NM_133523 1368657_at 15.775.6 18.979.6 14.577.2
MMP-7 a NM_012864 1368766_at 2.371.0a 18.579.3a 8. 777. 7a
MMP-8 NM_022221 1387735_at 15.674. 7 8.270.1 7.374.6
MMP-9 NM_031055 1398275_at 81.1729.4 10.578.9* 1.370.4*a
MMP-10a NM_133514 1368713_at 1.270.5a 1.670.1a 3.574.2a
MMP-11 NM_012980 1367858_at 34.777.3 76.5716.7* 41.6717.8
MMP-12 NM_053963 1368530_at 5.774.0a 259.67146.7* 134.7738.5*
MMP-14 RNMTMMP 1367860_at 77.5713.4 257.5782.4* 203.7755.2*
MMP-16 NM_080776 1368590_at 9.7711.5 17.372.6 5.274.4
MMP-23 NM_053606 1368961_at 46.674.3 45.4734.0 38.079.0
MMP-24 BF285924 1389833_at 355.0740.5 190.1723.3* 256.7753.4
TIMP-1 NM_053819 1367712_at 54.7712.1 451.37163.7* 255.17156.3*
TIMP-2 NM_021989 1386940_at 181.5730.9 485.0777.7* 287.3799.2*
TIMP-3 NM_012886 1368989_at 77.974.7 54.076.6 110.47109.4
ADAM-10 BI300565 1370955_at 18.475.0 22.071.9 21.078.8
ADAM-17 NM_020306 1367922_at 161.5710.6 273.2742.8* 183.2724.2
Mep1a NM_013143 1368236_at 2124.47106.8 473.47515.6* 1074.37575.0*
Mep1b NM_013183 1387158_at 1179.97121.7 343.37429.2 831.47478.4
TGF-b1 NM_021578 1370082_at 23.873.2 175.6733.2* 96.0717.2*
Collagen I a1 BI285575 1388116_at 45.376.4 337.17133.6* 159.2724.1
Collagen I a2 BI282748 1387854_at 49.477.5 208.2762.1* 137.7710.2
Collagen III a1 BI275716 1370959_at 95.0727.4 599.87254.1* 346.5742.5
Collagen IV a1 BE111752 1373245_at 357.6723.5 1145.77210.2* 658.17205.9
Proteoglycan core protein NM_020074 1368655_at 90.171.7 278.17113.7 172.0728.9
Affymetrix Rat Expression Array 230A GeneChip data, MAS5 normalized expression values (mean7s.d.; n=3 for each group: day 0, day +60 and day +100 after
transplantation).
*Significant difference (up or down) compared to day 0 (P-values o 0.05 by multiple group ANOVA analysis).
aAll absent calls (no expression).
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samples expressed MMP-8 at day þ 100 (n¼ 6). Also, MMP-8
was significantly increased at both time points of chronic
allograft rejection (Po0.05).
In general, the quantitative real-time PCR data reflect the
results obtained by the less quantitative GeneChip analysis
with the exception of two out of 12 genes, MMP-2 and
MMP-8. While MMP-8 is a low expressed gene with some
variability, as shown in Figure 2b, the discrepancy with
MMP-2 was further investigated.
Using a second primer/probe set taken from a different gene
location, we confirmed the increase in MMP-2 mRNA level
obtained by real-time PCR (Figure 2a),33 as described in the
Materials and Methods section. We obtained identical results as
compared to the first primer/probe set (data not shown).
Thus, we explained the discrepancies in the results for rat
MMP-2 expression observed by TaqMan reverse transcriptase-
polymerase chain reaction and Affymetrix genechips. Affy-
metrix probeset 1369825_at is based on 30 UTR sequence of
GenBank entry X71466. Owing to alternative splicing or
different processing, this untranslated region of rat MMP-2 is
not found in GenBank entry U65656. Therefore, most likely
our two TaqMan probes detected all splice variants of rat
MMP-2 and the Affymetrix probeset did not recognize the
U65656 variant of MMP-2 overexpressed in our rat model of
chronic rejection.
Subsequently, we excluded an effect of age on metzincin
expression. As we observed the most striking results at day
þ 60, we focused on this time point. Real-time PCR analyses
showed constant mRNA levels for MMP-2/-9/-12/-14, TIMP-2
and TGF-b1, in healthy F344 rats aged 10 weeks old
(corresponding to day 0 of our transplantation model;
n¼ 4) compared to healthy F344 rats that were 10 weeks and
60 days old (n¼ 4); data not shown. In addition, there was
also no difference in MMP-2 activity between both groups as
determined by zymography (data not shown).
Limited metzincin analyses have also been performed on
day þ 30 during the period of acute renal allograft rejection,
exactly between day 0 and day þ 60. The aim of these
studies was to investigate whether the pattern of metzincin
expression differentiates between acute and chronic rejection.
Significant upregulation of the following genes was observed
in acute graft rejection, as compared to healthy control
kidneys from day 0 (Po0.05): MMP-2 (7 ), MMP-12
(74 ), MMP-14 (7 ) and TIMP-2 (14 ). Again, MMP-9
displayed a marked downregulation (5 ; Po0.05). These
increases or decreases in gene regulation were also observed
in chronic rejection, as described. However, the degrees of
up- or downregulation of these MMP/TIMP occurred at a
significantly higher degree in acute rejection than in chronic
rejection at both time points (Po0.05 for all comparisons).
Investigation of MMP-2
Results of MMP-2 zymography are depicted in Figure 3a. The
upper panel shows a representative zymogram of two samples
per investigated group. The higher band at 72 kDa represents
pro-MMP-2 and the lower band at 62 kDa depicts the active
form of MMP-2.34 There is clearly a visible increase of MMP-2
activity, especially the pro-form, which can be seen at day
þ 60 during the chronic rejection process (lanes 3–4), as
compared to controls (lanes 1–2). The high activity levels
continued until day þ 100 (lanes 5–6).
The lower panel shows densitometric analysis of all
samples (mean7s.e.m.), obtained at day 0 (n¼ 8), day
þ 60 (n¼ 12), and day þ 100 (n¼ 6), respectively. Each
result is expressed as a percentage of the control at day 0
(100%). Pro-MMP-2 activity increased 3.4-fold during
rejection at day þ 60 (Po0.01) and 2.6-fold at day þ 100
(Po0.01), as compared with the control level at day 0.
Activity of the MMP-2 fragment had increased almost
1.5-fold at both time points (Po0.05).
Endogenous MMP-2 activity was also measured by
fluorometric analysis.35 The respective results (mean7s.e.m.)
are depicted in Figure 3b. MMP-2 activity at day þ 60
(n¼ 12) and day þ 100 (n¼ 6) was increased by 47 and 51%,
respectively, as compared to the control levels at day 0 (n¼ 8)
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Figure 2 | Relative mRNA levels of MMP, TIMP, ADAM-17, and
TGF-b1 by real-time quantitative PCR. (a) Overexpression of
MMP-2/-11/-12/-14, TIMP-1/-2 and TGF-b1 occurred during chronic
rejection at days þ 60 (n¼ 12) and þ 100 (n¼ 6), compared with
the control, at day 0 (n¼ 8). Furthermore, an upregulation of
ADAM-17 was significant at day þ 60. Although MMP-9 decreased
during chronic rejection, TIMP-3 remained unchanged. The
mRNA levels were normalized to GAPDH, calibrated to day 0
values (x-fold) (control¼ 1). *Po0.05 compared with the control
group. (b) All MMP-7 and half of the MMP-8 values in control samples
were below the detection limit with CT values X40. Nevertheless,
MMP-7 and MMP-8 were clearly detectable in most cases of chronic
rejection. Horizontal bars indicate medians of all samples per group.
Po0.05 compared with the control group.
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(Po0.05). Experiments were also performed in the
presence of phenylmethyl-sulfonylfluoride and phenantroline
to investigate the specificity of our assay (data not shown).
As expected, the addition of phenylmethyl-sulfonylfluoride, a
serine protease inhibitor, did not influence MMP activity. On
the contrary, phenantroline – a zinc-chelator and MMP
inhibitor – reduced the activity in all samples to almost zero.
Immunohistological staining of MMP-2 is depicted in
Figure 3c. During chronic rejection at day þ 60, MMP-2
expression is increased, as represented by a stronger staining
of the tubuli and to some extent in the glomerulus.
Investigation of MMP-9
MMP-9 protein level was further examined by Western blot,
zymography, and histological staining of allograft sections.
Western blot analysis of MMP-9 protein expression is
depicted in Figure 4a. We detected two bands (upper panel),
one at 130 kDa representing most likely the heterodimer of
MMP-9 and its major inhibitor TIMP-1, and another band at
92 kDa corresponding to the pro-form of MMP-9.36 How-
ever, at this stage it cannot be fully excluded that the band
observed at 130 kDa may also, in part, represent MMP-9
complexed with N-Gal.37
According to densitometric analysis (n¼ 6 per group), the
heterodimeric complex decreased by approximately 45 and
55% at days þ 60 and þ 100, respectively, as compared to
day 0 (Po0.05). The pro-form of MMP-9 decreased by
approximately 35 and 70% at days þ 60 and þ 100,
respectively, in comparison to day 0 (Po0.05). These results
are shown in Figure 4a (lower panel).
Immunohistological staining of MMP-9 is depicted in
Figure 4b. At day þ 60, MMP-9 expression is barely
detectable during chronic rejection. Strong staining of
MMP-9 was detected in the glomeruli of healthy kidney
from day 0 (as also shown by others).38
MMP-9 activity in zymograms of all samples was just at
the detection limit and therefore not usable for (semi-)
quantitative analysis (data not shown).
MMP-14 and TIMP-2 expression
A decisive role of MMP-14 and TIMP-2 in pro-MMP-2
activation is already well known.12,34,39,40 Thus, it was of great
interest to study MMP-14 and TIMP-2 genes, also at the protein
level. The synthesis of MMP-14 was investigated by Western
blot analysis, as depicted in Figure 5a, upper panel. MMP-14
was recovered in two different forms, as reflected by the bands
at 58 kDa corresponding to the active form of MMP-14 and at
70 kDa reflecting a dimer of MMP-14 and TIMP-2.12,34,39,40
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Figure 3 | MMP-2 activity and expression. (a) Zymography (upper panel), including densitometry (lower panel), showed increased activities of
pro-MMP-2 (72 kDa) and of active MMP-2 (62 kDa) at day þ 60 (lanes 3–4) and day þ 100 (lanes 5–6), as compared to the controls of day 0 in
lanes 1–2. Ctrl¼purified MMP-2 antigen (Calbiochem, Switzerland) as a reference for MMP-2 identification. *Po0.05 compared with the control
group. (b) Fluorometry confirmed increased MMP-2 activity (n¼ 6 per group). Each result is expressed as a percentage of the control value at
day 0 set at 100%. *Po0.05 compared with the control group. (c) MMP-2 immunohistology of the kidney sections. The presence of MMP-2 was
observed especially in the tubuli, but also to some extent in the glomeruli in case of chronic rejection at day þ 60 (right), compared to the
healthy control demonstrating only a positive staining in an arteriolar blood vessel (day 0, left).
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Figure 4 | MMP-9 protein expression. (a) Western blot analyses
(upper panel), including densitometry (lower panel), showed a
decreased presence of MMP-9/TIMP-1 (130 kDa) and of pro-MMP-9
(92 kDa) at days þ 60 (lanes 3–4) and þ 100 (lanes 5–6) compared
to day 0 (lanes 1–2). *Po0.05 compared with the control group.
(b) Immunohistology in the kidney sections. Negative or minimal
staining of MMP-9 in the glomeruli was observed in chronic rejection
(day þ 60, lower), compared to the positive control (day 0, upper).
Furthermore, there appears to be some peritubular MMP-9 staining in
control tissue.
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In this respect, densitometry revealed that active MMP-14
increased approximately fourfold at day þ 60 and day þ 100,
as compared to day 0 (Po0.01), as depicted in Figure 5a,
lower panel. MMP-14 complexed with TIMP-2 showed
threefold and sixfold increases at day þ 60 and day þ 100,
respectively (Po0.01).
The presence of TIMP-2 was demonstrated in three
different identifiable forms, as shown by Western blot
analysis depicted in Figure 5b, upper panel. The free form
of TIMP-2 at 27 kDa40 decreased by 39% (day þ 60) and
54% (day þ 100) during chronic rejection (Po0.05), as
represented by the respective densitometry (Figure 5b,
lower panel). The dimeric complex of TIMP-2 at 54 kDa
increased approximately 1.7-fold and 3.2-fold during the
course of chronic rejection (Po0.01). Finally, the bimole-
cular complex of TIMP-2 and MMP-14 at 70 kDa40 increased
1.7-fold and 3.4-fold at days þ 60 and þ 100, respectively
(Po0.01). The decrease of free TIMP-2 during chronic
rejection was probably due to its extensive recruitment to
form complexes.41
MMP-12 expression
The upregulation of MMP-12 observed at the mRNA level
was further investigated. The protein expression was analyzed
by Western blot, as depicted in Figure 6a. Two representative
samples of each category (day 0, day þ 60, day þ 100) are
shown. Pro-MMP-12 of 54 kDa and the intermediate form of
MMP-12 of 45 kDa (data sheet, Oncogene, 45) increased by
approximately 2.8-fold and 2.4-fold at day þ 60 and by 5.6-
fold and 4.9-fold at day þ 100 (Po0.05), respectively, as
depicted in Figure 6b.
Investigation of meprin
To substantiate the GeneChip results for meprin, real-time
reverse transcriptase-polymerase chain reaction was per-
formed to analyze meprin a and meprin b mRNA levels
during chronic rejection (Figure 7). For comparative analysis,
mRNA from non-transplanted kidneys at day 0 served as
healthy controls (set to 1.0).
Meprin a mRNA levels decreased to approximately 25
and 10% of controls at day þ 60 and day þ 100, respectively
(Po0.05). Meprin b mRNA decreased to about 25% of
controls at both time points (Po0.05).
The expression of meprin protein was assessed by Western
blot analysis. Two representative samples of each category
(day 0, day þ 60, day þ 100) are shown for meprin a and for
meprin b (Figure 8a, upper panel).
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Figure 5 | MMP-14 and TIMP-2 protein expression. (a) Upper panel:
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1–2), day þ 60 (lanes 3–4), and day þ 100 (lanes 5–6) after
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MMP-14 alone or in complex with TIMP-2 in control kidneys (n¼ 6) vs
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*Po0.05 compared with the control group.
0
1000
2000
3000
4000
5000
6000
7000
54 kDa 45 kDa
D
en
si
to
m
et
ry
 
(ar
bit
rar
y u
nit
s) Day 0
Day 60
Day 100
* 
* 
* 
* 
54 
45 
Day 0 Day 60 Day 100
kDaLanes 1 2 3 4 5 6a
b
Figure 6 | MMP-12 protein expression. (a) Western blot analyses of
pro-MMP-12 (54 kDa) and of the intermediate form of MMP-12
(45 kDa) in renal protein extracts from rats at day 0 (lanes 1–2), day
þ 60 (lanes 3–4), and day þ 100 (lanes 5–6). Representative results of
two animals per group are shown. (b) The densitometric analyses
were performed on three samples for each group. *Po0.05
compared with the control group.
Meprin 
Meprin   
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
Day 0 Day 60 Day 100
m
R
N
A 
re
la
tiv
e 
ex
pr
es
sio
n
* **
*
Figure 7 | Meprin a and b mRNA levels during chronic renal
allograft rejection. mRNA levels were measured using real-time
quantitative PCR in three groups of rats: at day 0 (n¼ 8) and during
chronic rejection at day þ 60 (n¼ 12) and at day þ 100 (n¼ 6).
Meprin mRNA levels decreased during chronic rejection at both time
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control group.
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In kidney tissue, the mature extracellular form of meprin
a has been shown to correspond to a molecular mass of
85 kDa.42,43 In accordance with real-time PCR results, this
form of meprin a was reduced during chronic rejection at day
þ 60 (Figure 8a, upper panel, lanes 3–4) and especially at day
þ 100 (lanes 5–6) after transplantation, as compared to
controls (day 0, lanes 1–2). Densitometric analysis of six
samples in each group is represented below (Figure 8a, lower
panel). It shows a reduction of the 85 kDa band by
approximately 40 and 85% at day þ 60 and day þ 100,
respectively (Po0.01). Additional bands appeared along the
process of chronic rejection at a lower molecular weight, in
the order of 75 kDa. The identity of this form of meprin a
was not investigated further, but it cannot be excluded that
they represent degraded forms of meprin.
The major form of renal meprin b has a molecular mass of
110 kDa. Meprin b expression decreased at day þ 60 (Figure
8a, upper panel, lanes 3–4) and at day þ 100 (lanes 5–6) as
compared to controls (day 0, lanes 1–2). The densitometric
analysis of six samples in each group demonstrated a
reduction of meprin b protein levels during chronic rejection
by 46% at day þ 60 and by 70% at day þ 100 after trans-
plantation (Po0.01), as depicted in Figure 8a (lower panel).
As expected, immunohistological staining for meprin
a and b in tissue sections of control kidneys at day 0 revealed
strong localization of both subunits at the brush border
membrane of proximal tubular cells (Figure 8b, left panel).
During chronic rejection at day þ 60, meprin a was not
detectable (Figure 8b, upper right picture) and staining for
meprin b was significantly weaker (Figure 8b, lower right
picture) than in the respective control tissues.
Thus, the downregulation of meprin a and b at the brush
border membrane of proximal tubular cells is compatible with
the results of mRNA and protein expression described above.
Combined meprin a and b activity was determined
using N-benzoyl-L-tyrosyl-p-aminobenzoic acid as substrate
(Figure 8c). The endogenous activity of meprin decreased by
approximately 70% at days þ 60 and þ 100 after transplant-
ation compared to day 0 (0.008 vs 0.026mmol/ml/h/mg
protein) (Po0.05). Meprin is synthesized as a zymogen, which
may be activated by trypsin. Therefore, we pretreated protein
extracts with trypsin in vitro to measure total meprin activity.
Total activity was 6.5-fold higher than endogenous activity at
day 0 (0.173 vs 0.026mmol/ml/h/mg protein; Po0.05),
indicating that only a minor portion of meprin is endogen-
ously active in the kidney in vivo. However, during chronic
rejection at days þ 60 and þ 100, a similar decrease by
approximately 80% was observed in the case of total meprin
activity (0.03mmol/ml/h/mg protein; Po0.05).
DISCUSSION
The present investigation analyzes the expression and activity
of metzincins in chronic renal allograft rejection. These
proteases were investigated as they represent a growing
superfamily of key regulators of ECM metabolism and of cell
proliferation.
We studied three members of the metzincin superfamily:
MMP (including TIMP), meprin a/b and ADAM-17. Our
findings indicate that MMP/TIMP (with the exception of
MMP-9) are upregulated and meprin a/b are downregulated
in chronic renal allograft rejection.
In humans, increased circulating levels of MMP-1 were
found in subjects with acute kidney allograft rejection, whereas
concentrations of MMP-2 and MMP-3 were increased in
patients with chronic transplant nephropathy.44,45
MMP and TIMP have been investigated in a rat model of
acute kidney transplant rejection using a Buffalo donor to a
Wistar-Furth recipient.12 Increased graft levels of pro-MMP-2/
0
20
40
60
80
100
120
Day 0 Day 60 Day 100
D
en
si
to
m
et
ry
 (%
 of
 da
y 0
)
*
*
*
* 
85 
Day 0
Day 0 Day 60
Day 60 Day 100
Lanes 1 2 3 4 5 6
kDa
110 
Meprin  
M
ep
rin
 
 
Meprin  
M
ep
rin
 
 
Meprin  
Meprin  
0.00
0.05
0.10
0.15
0.20
Endogenous activity Total activity
PA
B
A
 p
ep
tid
e 
hy
dr
ol
yt
ic
 a
ct
iv
ity
(u
mo
l/m
l/h
/m
g p
ro
tei
n)
* * 
* 
* 
Day 0 
Day 60
Day 100 
50 m 50 m 
50 m 50 m 
a b c
Figure 8 | Meprin protein synthesis. (a) Upper panel: Western blot analyses of meprin a (85 kDa) and meprin b (110 kDa) (upper panel) in renal
protein extracts from rats at day 0 (lanes 1–2), day þ 60 (lanes 3–4) and day þ 100 (lanes 5–6) after transplantation. Representative blots of two
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compared with the control group.
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-9/-14 and active MMP-14 but decreased concentrations of
activated MMP-2/-9, TIMP-2 and of inactive fragments of
MMP-14 were reported.12 In a previous study, we have
investigated the role of MMP in the Dark Agouti to Lewis
model of severe acute renal allograft rejection.46 However, the
synthetic MMP inhibitor BB-94 did not show a clear benefit
on renal histology and on proteinuria.46
Taken together, in severe acute rejection, metzincins may
be somewhat redundant due to the magnitude of other
activated inflammatory mediators. The role of MMP in
chronic renal allograft rejection may be more important, as
quantitative and qualitative alterations in the ECM compart-
ment represent the most characteristic findings in this
rejection process.
In the present study, we utilized the F344 to LEW rat
model of chronic renal allograft rejection.29,30 LEW recipients
of F344 allografts develop acute rejection at around day þ 25
lasting for several days and leading to graft loss in the
order of 50%. The surviving rats demonstrate histological
and functional characteristics of chronic rejection from
day 50 onwards, without concomitant immunosuppressive
treatment.
Chronic renal allograft rejection led to increased mRNA
levels of key MMP, such as MMP-2/-11/-12/-14, and their
inhibitors, TIMP-1 and TIMP-2. In parallel, we demonstrated
increased MMP-2 activity and synthesis. Accordingly, aug-
mented levels of MMP-2 mRNA have been reported by others
during chronic allograft nephropathy in humans.47
TIMP-2 represents the main inhibitor of MMP-2, but
it also forms complexes with MMP-14 to activate
MMP-2.12,34,39,40 Therefore, we investigated TIMP-2 and
MMP-14 in more detail. In fact, an increased production of
TIMP-2 and MMP-14 alone and in complexes was demon-
strated at the protein level.
MMP-12 (metalloelastase) showed the strongest increase
of any type of metzincin with an approximately 70-fold
augmented mRNA level during chronic allograft rejection.
Although the role of MMP-12 in rejection processes remains
to be defined, MMP-12 was previously shown to play a role
in inflammation. MMP-12 appeared to support leukocyte
influx and to be necessary for the development of acute
alveolitis in a mice model of lung injury.48
Surprisingly, MMP-24, and especially MMP-9, decreased
substantially during allograft rejection. To our knowledge,
this is a novel finding without any precedence, which
warrants further investigation. Nevertheless, due to a
relatively low overall expression, MMP-9 appears to represent
a marker of rejection processes rather than a pathophysio-
logic relevant factor. This has been demonstrated in a group
of patients with chronic glomerulonephritis, where
MMP-2 was found to be increased and MMP-9 to be
downregulated.35
Among the ADAM family of proteases, we investigated
ADAM-17 (tumor necrosis factor-a (TNF-a) converting
enzyme). ADAM-17 processes TNF-a and represents a validated
therapeutic target for anti-inflammatory interventions.28,49
In our studies, ADAM-17 clearly increased during chronic
renal allograft rejection at day þ 60. Thus, the inhibition of
ADAM-17 offers a new perspective for the treatment or
prevention of chronic allograft nephropathy.
In our model, meprin was significantly downregulated as a
result of the chronic rejection process. Interestingly, accord-
ing to the microarray data, meprin was by far the strongest
metzincin expressed in healthy control kidneys.
The decrease of meprin was demonstrated at the mRNA
level, visualized by microarrays and real-time quantitative
PCR, and at the protein level, determined by Western blot,
immunohistology and activity tests. The presence of smaller
molecular forms of meprin a suggests that this subunit may
be partially degraded during rejection. Accordingly, renal
meprin activity had decreased substantially. Because meprin
is mainly expressed in the brush border of renal tubular cells,
the decrease of meprin may be the consequence of tubular
alterations or even destructions in chronic renal allograft
rejection. However, the increase of TGF-b in chronic
rejection may also be in part responsible for the decrease in
meprin activity by its inhibitory effect on plasmin activity
and stimulatory action on PAI-1 synthesis.50,51
The pattern of differentially regulated metzincins may lead
to novel diagnostic markers of renal allograft rejection. As
an example, this may be relevant for MMP-12 particularly
using microarrays, as our Affymetrix GeneChip failed to
detect this protease in healthy control kidneys, but showed a
very strong signal in chronic rejection. Furthermore,
upregulated MMP may also represent individual targets for
therapeutic interventions.
According to our limited results, the altered pattern of
metzincin expression does not distinguish between acute and
chronic renal allograft rejection, although further investi-
gation is warranted to definitely resolve this issue.
As we did not perform an interventional investigation, we
cannot determine whether the alterations in metzincin
expression are beneficial or detrimental. For future interven-
tions, MMP activity can be inhibited by synthetic MMP
inhibitors. We have previously shown that hydroxamate-
based MMP inhibitors inhibit cell proliferation and matrix
accumulation in analyses of cultured mesangial cells and of
anti-Thy1.1 nephritis.52–54
Angiotensin-converting enzyme inhibitors also inhibit
MMP activity35 and the angiotensin-converting enzyme
inhibitors enalapril ameliorated chronic renal allograft
rejection in the F344 to LEW rat strain combination.55 Thus,
a part of the therapeutic benefit of angiotensin-converting
enzyme inhibitors may be the consequence of concomitant
MMP inhibition.
In conclusion, metzincins, such as MMP, ADAM-17,
meprin, and TIMP, are dysregulated in chronic renal allograft
rejection. Therefore, metzincins may represent novel diagno-
stic markers for chronic renal allograft rejection. Furthermore,
upregulated MMP, TIMP, and ADAM-17 may provide novel
therapeutic targets for the prevention and treatment of chronic
rejection processes.
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MATERIALS AND METHODS
Animals
Male inbred F344, RT1lv1, and LEW, RT1l rats (250 g body weight)
were obtained from Harlan, Horst, The Netherlands.29,30
Kidney transplantation
Kidney transplantation was performed by SA Joosten and C van
Kooten, as described previously.29,30 Briefly, the left kidney of the
LEW recipient was removed and orthotopically replaced by the F344
donor kidney. The contralateral F344 kidneys of the donor were
used as healthy controls of day 0. A patch of the donor aorta and the
inferior vena cava was anastomized to the corresponding recipient’s
blood vessels. Anastomosis of the donor urethra was performed end-
to-end. Nephrectomy of the remaining native kidney occurred at
day þ 7 after transplantation. For our analyses, recipients were
killed at day 0, day þ 30, day þ 60, and day þ 100 postoperatively.
To exclude an effect of age on metzincin expression, we included
an additional control group of healthy F344 rats that were 10 weeks
and 60 days old at the time of analysis.
Analysis of renal histology by periodic acid-Schiff staining and of
microalbuminuria was performed as described.29,30 Serum creati-
nine levels were determined by routine methodology.
RNA isolation
Total RNA was isolated from frozen tissues according to the
manufacturer’s instructions (RNeasy; Qiagen, Zurich, Switzerland)
and stored at 701C. RNA of high quality was obtained, as assessed
by Bioanalyzer 2100 electropherograms (Agilent).
GeneChip expression profiling
DNA microarray analysis was performed using GeneChip hybridiza-
tion according to the manufacturer’s instructions (Affymetrix).
Affymetrix Rat Expression Array 230A GeneChips comprise
15 924 probe sets (25mer oligonucleotide probes; 11 probe
pairs/set). Briefly, 5 mg total RNA was reversed transcribed into
double-strand cDNA in the presence of a (dT)24/T7 primer. Labeled
cRNA was synthesized by T7 RNA polymerase in the presence
of biotinylated ribonucleotides and hybridized overnight to the
GeneChips followed by a 2-h washing and staining using
streptavidin-coupled phycoerythrin. Finally, each GeneChip
was scanned by a laser scanner. The images were processed
using the Microarray Analysis Suite (Affymetrix) version 5
(MAS5). All expression experiments were scaled to the same target
intensity (150).
Reverse transcription
Total RNA (0.5–1 mg/ml final concentration) was first treated with
DNase I (Sigma). One microgram of DNase-treated total RNA was
reverse transcribed at 601C for 1 h in a reaction mixture containing a
final concentration of 1 mM of deoxynucleotide triphosphates
(Promega), 2.5mM random hexamer primers, 1 PCR buffer II,
5 mM MgCl2, 1 U/ml RNase inhibitor, and 2.5 U/ml of Murine
Leukemia Virus Reverse Transcriptase (Applied Biosystems).
Complementary DNA was stored at 201C until real-time
quantitative PCR (TaqMan PCR).
Real-time TaqMan PCR analysis
The PCR conditions were established according to the instructions
of Applied Biosystems (Rotkreuz, Switzerland). The respective
cDNA was used in duplicate as a template for the real-time PCR
analysis with the ABI PRISM 7000 Sequence Detection System
(Applied Biosystems). The thermal cycle profile was 951C for 15 s
and 601C for 1 min, repeated 45 times. To detect genomic DNA
contaminations, all analyses included minus reverse transcriptase
samples as negative controls.
GAPDH expression levels were analyzed in all samples as a
housekeeping gene to normalize expression between different samples
and to monitor assay reproducibility. Relative quantification of all
targets was calculated by the comparative cycle threshold method
outlined by the manufacturer (User Bulletin No. 2; Applied Biosystems).
MMP-2/-9/-14 and GAPDH. TaqMan PCR primers and probes
were designed by using the Primer-Express software (Applied
Biosystems).56,46 One microliter cDNA solution containing 50 ng of
reverse-transcribed total RNA was added to 24 ml of PCR reaction
mixture. Reaction mixtures were composed as follows: TaqMan
Universal PCR Master Mix (Applied Biosystems; containing
AmpliTaq Gold DNA Polymerase) final concentration 1 , and
300 nM Probe, 300 nM forward primer and 900 nM reverse primer for
GAPDH, MMP-256,46 and MMP-9 assays, respectively, or 150 nM
Probe, 400 nM forward primer and 400 nM reverse primer for MMP-
14 assay, or 100 nM Probe, 300 nM forward primer and 300 nM
reverse primer for the second MMP-2 assay.33 The primer
concentrations for each assay were determined previously following
the Applied Biosystems manual.56,46
MMP-7/-8/-11/-12, TIMP-1/-2/-3, ADAM-17, TGF-b1 and meprin
a/b. Assays-on-Demand Gene Expression Products were used as
described in the manufacturer’s protocol (Applied Biosystems).
Protein extraction from kidney tissues
Frozen half-kidneys were minced on a cold Petri dish and
transferred into separate tubes. Thereafter, 1 ml of lysis buffer
(0.1 M Tris-HCl containing 0.1% Tween 80, pH 7.5 and 1 mg/ml
Leupeptine) per 50 mg of wet tissue was added to perform enzyme
activity analyses. For Western blot analyses, proteins were
extracted in 25 mM Tris-HCl, 50 mM NaCl, pH 8.0, supplemented
with 1% deoxycholic acid, 1% nonidet-P40, and one tablet per
10 ml extracting buffer of protease inhibitor cocktail (Complete
Mini EDTA free; Roche Diagnostics, Rotkreuz, Switzerland). After
homogenization, samples were centrifuged twice at 10 000 g for 10
and 5 min, respectively, to remove cell debris. Extracted super-
natants were stored at 201C. Protein concentrations were
determined using the BCA protein assay reagent kit (Pierce,
Lausanne, Switzerland).
MMP-2 and MMP-9 activity
Activities of these two gelatinases in frozen kidney samples were
analyzed by gelatin substrate zymography (MMP-2/-9) and
fluorometry (MMP-2), exactly as previously described by us.46,52,35
Note, homogenized samples were used as is and were not further
concentrated before their analyses.
Western blot analyses of MMP-9/-12/-14, TIMP-2
and meprin a/b
Western blot analyses were performed as described previously with
some minor changes.35 Following two washes in Tris buffered saline
with 0.1% Tween, the blots were incubated overnight at room
temperature by gently shaking in Tris buffered saline with 0.1%
Tween/3.5% dry milk containing monoclonal mouse anti-MMP-9,
anti-MMP-14 or anti-TIMP-2 (dilutions 1:50, 1:25 or 1:100,
respectively; Oncogene, Lucerne, Switzerland), or polyclonal goat
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anti-mouse MMP-12 (dilution 1:200; Santa Cruz Biotechnology,
Inc.) or polyclonal rabbit anti-human meprin a or b antibodies
(1:1000). Note, anti-human meprin antibodies were obtained from
E Sterchi and co-workers57 and were shown to crossreact with
mouse and rat meprin (E Sterchi, personal communication).
Subsequently, the blots were washed extensively in Tris buffered
saline with 0.1% Tween for 1 h (4 15 min) and incubated with goat
anti-mouse or goat anti-rabbit (donkey anti-goat for MMP-12)
HRP-conjugated secondary antibody. Finally, the membranes were
incubated with enhanced chemiluminescent reagents for 5 min
(Amersham Pharmacia Biotech, Du¨bendorf, Switzerland), followed
by exposure to Hyperfilm enhanced chemiluminescent (Amersham
Pharmacia Biotech). The molecular weight of the bands of interest
was determined by a precision molecular weight marker from
Biorad (Reinach, Switzerland).
Immunohistology of MMP-2 and MMP-9
Immunohistochemistry of MMP-2/-9 was performed using the rat
renal cortex, as described previously.35
Immunohistology of meprin a and meprin b
The 2–3mm paraffin-embedded kidney sections were dewaxed,
rehydrated and pretreated by boiling in 10 mM citrate buffer, pH
5.65, in a microwave oven. Thereafter, and following all subsequent
steps, sections were washed in Tris-buffered saline and blocked for
30 min with Tris-buffered saline containing 20% porcine serum.
Samples were incubated for 35 min at room temperature with primary
antibodies in Tris-buffered saline/5% porcine serum (rabbit anti-
meprin a or anti-meprin b 1:2500). After washing 3 times for 10 min,
sections were incubated for 35 min with biotinylated porcine-anti-
rabbit immunoglobulin antiserum (dilution 1:300 from DakoCytoma-
tion, Glostrup, Denmark). Thereafter a streptavidin—biotin complex/
alkaline phosphatase (1:50 in Tris-buffered saline) (DakoCytomation)
was applied for 35 min. Sections were developed for 1 min in new
fuchsin–levamisol (DakoCytomation), counterstained with hematoxy-
lin (Merck, Dr Grogg Chemie, Stettlen-Deisswil, Bern, Switzerland)
and finally mounted with Aquatex (Merck).
Meprin activity
Activity of meprin a and meprin b was assessed as outlined
previously.25 To measure total activity, a portion of the samples
obtained from protein extraction described above was activated at 371C
for 2 h with 20mg/ml trypsin. Before the meprin activity assay, trypsin
was inhibited with 50mg/ml of soybean trypsin inhibitor (Sigma, Dr
Grogg Chemie, Stettlen-Deisswil, Bern, Switzerland). Meprin activity
was measured using the N-benzoyl-L-tyrosyl-p-aminobenzoic acid24 as
substrate. After incubating samples at 371C for 4 h with substrate (1:1,
v/v), the reaction was stopped by the addition of 400ml of 10%
trichloroacetic acid. Precipitated proteins were removed by centrifuga-
tion. The p-amino-benzoic acid contained in 100ml of cleared
supernatant was subjected to a colorimetric reaction according to
Bratton-Marshall by the addition of 200ml of NaNO2, 200ml of
ammonium sulfamate and 500ml N-(naphtyl)-ethylene diamine.
Photometric readings were taken at 546 nm including a standard
solution of known benzoic acid concentration, and results were
expressed as mmol/ml/h/mg of total protein.
Statistical analysis
The differences between mean values were analyzed by non-
parametric Mann–Whitney test for variables that were not normally
distributed. Results were confirmed by the one-way analysis of
variance Kruskal–Wallis test. All statistical tests were two sided. Only
the analyses of MMP-7 and MMP-8 were performed using the
unpaired t-test.
Statistical analysis was performed with the GraphPad Prism
Software version 3.02 for Windows (Graphpad Software, San Diego,
CA, USA). Results are given as mean7s.e.m. for continuous
variables. Microarray and real-time PCR results were expressed
as mean7s.d., as described previously.46 For all experiments,
probability of error (P-values) was calculated. Values for Po0.05
were regarded as significant.
Genechip MAS5 normalized expression values were subjected to
analysis of variance and Kruskal–Wallis group statistical analyses.
Further analyses were performed by GeneSpring 6.1.1 (Silicon
Genetics).
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